Eric Peterson

Core Faculty

Eric D. Peterson, MD, MPH, FAHA, FACC

Contact

peter016@mc.duke.edu

Degree

MD, University of Pittsburgh

Dr Peterson is the Principal Investigator of the National Institute of Health, Lung and Blood Institute (NHLBI) Coordinating Center for its Outcome Research Network, and the Agency for Healthcare Research and Quality (AHRQ) Cardiovascular Center for Education and Research on Therapeutics (CERTs). He is also the Principal Investigator of the Data Coordinating Centers for the Society of Thoracic Surgeons (STS), National Cardiac Surgery Database, the American College of Cardiology National Cardiac Database (ACC-NCDR) and the American Heart Association Get With the Guidelines Database (AHA-GWTG).

Dr Peterson participates on multiple national committees, as well as CV guideline and performance measure development groups. Dr Peterson is a member of the American Society for Clinical Investigation (ASCI), the Association of American Physicians (AAP), and the Association of University Cardiologists (AUC).

In 2013, Dr Peterson received the American Heart Association Meritorious Achievement Award and was voted one of world’s top 400 most influential researchers in biomedicine. This year, he was named by Thomson Reuters as a ‘Highly Cited Researcher’, ranking him among the top 1% most cited in clinical medicine. He is a Contributing Editor on the Journal of the American Medical Association and is a recognized leader in outcomes and quality research with over 800 peer-reviewed publications in the field.

From Scholars@Duke

Scholars@Duke Profile

Nelson AJ, Navar AM, Mulder H, Wojdyla D, Philip S, Granowitz C, et al. Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial). Am J Cardiol. 2020 Oct 1;132:36–43.

Madhavan M, Holmes DN, Piccini JP, Freeman JV, Fonarow GC, Hylek EM, et al. Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). Am J Cardiol. 2020 Oct 1;132:66–71.

Nanna MG, Chen ST, Nelson AJ, Navar AM, Peterson ED. Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan Policy. Jama Intern Med. 2020 Sep 8;